Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Brain cancer: Typical mutation in cancer cells stifles immune response

The exchange of a single amino acid building block in a metabolic enzyme can lead to cancer.

In addition, it can impair the immune system, scientists from the German Cancer Research Center (DKFZ), the University Hospitals in Mannheim and Heidelberg, and the German Cancer Consortium now report.

It thus blocks the body's immune response in the battle against the mutant molecule and also impedes immunotherapy against brain cancer.

This finding opens new insights into cancer development and progression and it also suggests that rethinking antitumour immunotherapy is required.

Alterations in the genetic material are often the first step in carcinogenesis.

In many cases, an exchange of a single amino acid building block is all it takes.

A prime example for this is the mutant form of a metabolic enzyme called IDH1 (isocitrate dehydrogenase 1).

This enzyme has an important task in cellular energy metabolism.

However, if IDH1 has undergone an alteration at a specific site, it leads to the formation of a substance called 2 HG, which harms the body.

It disturbs the metabolism and stimulates cell division, thus laying the cornerstone for cancer.

The scientific term for a cancerogenic metabolic product like 2-HG is "oncometabolite".

2-HG accounts for more than 70 percent of all low-grade gliomas, a type of brain cancer.

Scientists from the German Cancer Research Center and the University Hospitals in Mannheim and Heidelberg have now found that the oncometabolite additionally impairs the body's immune response.

Normally, the immune system recognises mutant IDH1 as foreign.

The altered molecule in the tumour should therefore attract immune cells.

Based on this finding, scientists already developed a vaccine that sensitises the immune system for the battle against brain tumours exhibiting the special IDH1 mutation.

However, the opposite is the case, according to Michael Platten, a neurologist who leads a research department at the DKFZ and is director of the Neurology Department of University Medicine Mannheim (UMM).

"In the immediate environment of tumours with the specific mutation in IDH1, we find only very small quantities of immune cells, which are additionally impaired in their functioning," Platten said. "This made us curious and we aimed to find out whether and how the 2-HG oncometabolite directly influences the immune system."

The investigators discovered that the tumour cells release 2-HG into their environment.

T cells - immune cells of the body with an important role in the fight against cancer cells - take up released 2-HG.

This subsequently blocks important signalling pathways in the T cells and the immune cells are re-programmed from an active to an inactive state.

"This might explain why the immune system fails to suppress the development of these tumours even though it is essentially capable of fighting tumour cells with the mutant IDH1 molecule," said Lukas Bunse, DKFZ and Heidelberg University Hospital, who is one of the first authors of the publication in Nature Medicine.

However, the scientists have also found a method to avoid this blockade.

They administered an inhibitor developed by the team led by DKFZ researcher Andreas Deimling to mice with IDH1 mutant tumours.

The inhibitor blocks the mutant IDH1 molecule so that no 2-HG forms in the tumour cells.

Subsequently, the investigators in fact found larger quantities of active immune cells in the tumours and their immediate environment.

In addition, immunotherapy combined with the inhibitor was substantially more effective.

Platten thinks that this finding has potential of learning more about other tumours and their treatment. "We now know several of these oncometabolites in different tumour types," the neuroimmunologist said. "It would be interesting to investigate whether suppression of the immune response might be a higher principle in oncometabolites."

The results obtained by the DKFZ researchers already point in a new direction in the treatment of IDH1 mutant tumours.

"In future immunotherapies, we will have to attack from two sides," according to Platten, because it has become clear that it is not enough to prime the body's defense mechanisms to attack the mutant IDH1 molecule. "We must additionally block the target protein using a specific inhibitor in order to prevent the production of 2-HG and the resulting suppression of immune response."

Source: German Cancer Research Center



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation